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Mitochondria are cellular energy generators whose activity requires a continuous supply of oxygen. Recent genetic analysis has
suggested that defects in mitochondrial quality control may be key factors in the development of Parkinson’s disease (PD).
Mitochondria have a crucial role in supplying energy to the brain, and their deterioration can aﬀect the function and viability
of neurons, contributing to neurodegeneration. These organelles can sow the seeds of their own demise because they generate
damaging oxygen-free radicals as a byproduct of their intrinsic physiological functions. Mitochondria have therefore evolved
speciﬁc molecular quality control mechanisms to compensate for the action of damaging agents such as oxygen-free radicals.
PTEN-induced putative kinase 1 (PINK1) and high-temperature-regulated A2 (HTRA2), a mitochondrial protease, have recently
beenproposedtobekeymodulatorsofmitochondrialmolecularqualitycontrol.Here,wereviewsomeofthemostrecentadvances
in our understanding of mitochondria stress-control pathways, focusing on how signalling by the p38 stress kinase pathway may
regulate mitochondrial stress by modulating the activity of HTRA2 via PINK1 and cyclin-dependent kinase 5 (CDK5). We also
propose how defects in this pathway may contribute to PD.
1.Introduction
In evolutionary terms, the increase in energetic demands
resulting from the evolution of small, prokaryotic organisms
to larger, eukaryotic cells was achieved through the internal-
isation of energy-generating factories that ultimately led to
theemergenceofmodernmitochondria[1].Suchanincrease
in energy output also resulted in detrimental consequences
because these organelles are the main intracellular sources
of damaging oxygen-free radicals. These reactive oxygen
species (ROS) can be destructive, attacking various cellular
components, including DNA, proteins, lipids, and carbohy-
drates,butcanalsoactasregulatorsofintracellularsignalling
pathways [2]. Eukaryotic cells have evolved strategies to cope
with the damage caused by excess levels of damaging agents
such as ROS. Recent ﬁndings from genetic studies suggest
that the defective sensing of mitochondrial damage may play
an important role in the development of neurodegenerative
diseases such as Parkinson’s disease (PD) (reviewed in [3]).
An eﬀective response to such damage can be described in
three diﬀerent steps: (1) damaged components need to be
recognised by sensing mechanisms, (2) the sensing mech-
anisms must convey a signal to damage suppressors, and
(3) the activity of damage suppressors must be increased to
promote the disposal of damaged cellular components.
In this paper, we provide an overview of the research that
focuses on how pathways aﬀecting mitochondrial quality
control may play a role in the aetiology of PD. We place
particular emphasis on a recently identiﬁed mitochondrial
damage response pathway regulated by p38 kinase and
summarise some of the recent molecular determinants of
mitochondrial quality control regulated by this kinase.
2. Parkinson’sDisease and
Mitochondrial Dysfunction
PD is a common neurodegenerative disease characterised by
the progressive loss of dopaminergic neurons in the nigros-
triatal region of the brain. Most PD cases occur sporadically2 International Journal of Cell Biology
(i.e., they are of unknown cause). However, 10–15% of PD
patients have a family history of the disease, indicating that
thereisastronggeneticbasisforthisdiseaseinthissubgroup.
The molecular pathogenesis of sporadic PD and the basis for
selective dopaminergic neuron loss remain unknown, and
it is unclear whether gene mutations are involved in the
development of this disease in sporadic PD patients. Epi-
demiological studies consistently link exposure to pesticides
to a higher incidence of PD. In particular, pesticides that
cause an increase in ROS, such as rotenone and paraquat,
have been shown to cause PD-like conditions in rodent
models [4]. In addition, the mitochondrial toxin 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was shown to
be responsible for the onset of severe PD-like symptoms
in a group of young drug users in the 1980s. Drugs such
as rotenone, paraquat, and MPTP disrupt normal electron
transport chain (ETC) in the mitochondria, leading to an
increase in free radical generation. Through the generation
of ROS, exposure to mitochondria-damaging agents may
be important in the aetiology of PD in sporadic patients.
Althoughmitochondrialdysfunctionhasbeeninconclusively
linked to PD in the past few decades, genetic evidence
indicating mitochondrial involvement in this disease was
recently obtained. A major advance occurred in a recent
study in which researchers identiﬁed disease-causing PINK1
mutationsinfamilialPD[5].Mutationsinthemitochondrial
serine protease HTRA2 were also reported to be associated
withPDinsporadicpatients[6];however,theroleofHTRA2
in PD remains controversial [7].
3. Mitochondria as the Major Source of
Intracellular ROS
Mitochondria are the powerhouses of eukaryotic cells and
are responsible for most of the ATP synthesis via oxidative
phosphorylation(OXPHOS).DuringOXPHOS,NADH,and
FADH2 produced by glycolysis and the tricarboxylic acid
(TCA) cycle are used as electron donors and transported
through the ETC via a series of redox reactions that involve
four molecular complexes (Complexes I, II, III, and IV).
Oxygen is used as the ﬁnal electron acceptor and is reduced
to water through the acquisition of four electrons. The
transport of electrons through the ETC is coupled to the
discharge of protons from the mitochondrial matrix to the
intermembrane space. The discharge of protons leads to
the generation of a proton gradient that is necessary for
the synthesis of ATP from ADP by ATP synthase. During
transport through the ETC, a small portion of electrons (1–
3%) escape prematurely, mainly from Complexes I and III,
and directly reduce oxygen, generating the superoxide anion
(O2
•−).TheseROScaninteractwithothermoleculestoform
other types of ROS, such as hydrogen peroxide (H2O2)a n d
the hydroxyl radical (OH•). In addition to the ETC, other
mitochondrialcomponentsareknowntogenerateROS,such
as α-ketoglutarate dehydrogenase (α-KGDH) and pyruvate
dehydrogenase, which generate both the superoxide anion
(O2
•−) and hydrogen peroxide (H2O2)[ 8, 9]. In addition
to the physiological ROS produced by normal mitochon-
drial activity, nonphysiological increases in ROS levels can
occur in conditions of stress, such as nutrient deprivation
or hypoxia, or as a consequence of the deterioration of
mitochondrial enzymes. The increase in ROS concentration,
a condition known as oxidative stress, can be detrimental
for the mitochondria and the entire cell because of the
capacity of ROS to damage several cellular components,
including proteins, lipids, and nucleic acids. To cope with
the detrimental eﬀects of ROS, mitochondria are equipped
with several antioxidant systems that comprise a ﬁrst line
of defence against these toxic agents. Of these systems, the
most important is manganese SOD (Mn-SOD). Mn-SOD is
ah i g h l ye ﬃcient enzyme (Kcat ∼ 109 M−1 sec−1)l o c a l i s e dt o
the mitochondrial matrix that can quickly dismutate super-
oxide anions (O2
•−)t oh y d r o g e np e r o x i d e( H 2O2)a n d
molecular oxygen (O2). In addition to Mn-SOD, mito-
chondrial antioxidant defences include the thioredoxin-2
(Trx2) system, formed by Trx2 and thioredoxin reductase 2
(TrxR2), and peroxiredoxin-3 (Prx3); both are involved in




Paradoxically, even though mitochondria-generated ROS are
clearly viewed as damaging agents, they can also play an
active role in intracellular signalling. Hydrogen peroxide, but
not the superoxide anion, can easily cross the mitochondrial
membranes and diﬀuse into the cytosol, where it can
negatively aﬀectthe structure and function of proteins by the
speciﬁc oxidation of reactive cysteine residues to sulphenic
acid (–SOH) (reviewed in [11]). Sulphenic acid is a very
reactive and unstable chemical and, together with ROS, can
further react with a second molecule of H2O2 to form a
sulﬁnic acid derivative (–SO2H). Oxidation to sulﬁnic acid
is, with some exceptions, an irreversible modiﬁcation that
can permanently alter the structure and function of a protein
and can ultimately result in cellular damage and death.
Under physiological conditions, sulphenic acid derivatives
can be reduced back to the thiolate form or transformed
into a number of thiol adducts by reactions such as S-
glutathionylation to form protein-GSH mixed disulphide, a
stable and reversible oxidation state that can be eﬃciently
r e d u c e db a c kb yr e a c t i o n sc a t a l y s e db yT r xa n dp e r o x i r e -
doxins. The reversible oxidation of cysteines by ROS, in
particular H2O2, allows these molecules to be classiﬁed as
second messengers, which lead to the activation of signalling
pathways. Of these, pathways mediated by mitogen-activated
protein kinases (MAPKs) are some of the best studied and
characterised.
MAPKs are a family of evolutionarily conserved serine/
threonine kinases involved in the regulation of several cellu-
lar processes, such as growth, diﬀerentiation, and apoptosis.
A typical MAPK cascade includes a MAPK kinase kinase
(MAP3K) that phosphorylates a MAPK kinase (MAP2K),
which in turn phosphorylates a MAPK. Active MAPKs,
through direct phosphorylation, regulate the activity of
many cytoplasmic and nuclear targets. The switch from aInternational Journal of Cell Biology 3
redox signal to a phosphorylation cascade can occur at dif-
ferent levels of the MAPK pathway, such as at the level of the
MAP3Ks,someofwhich(e.g.,ASK1andMEKK1)areredox-
sensitive proteins. ASK1, in particular, plays a key role in the
cellular response to oxidative stress because it can activate
both JNK and p38 pathways through the phosphorylation of
their upstream kinases MKK4/7 and MKK3/6, respectively
[12]. The activation of ASK1 is regulated by its redox-
sensitive binding with thioredoxin-1 (Trx1), an antioxidant
proteininvolvedinthereductionofdisulphidebonds.Under
physiological conditions, one of the two cysteines in the
activesiteofTrx1bindsandinactivatesASK1;whenoxidative
stress occurs, the Trx1 cysteines form an intramolecular
disulphide bond, and the protein loses its interaction with
ASK1, which becomes active and can activate downstream
factors [13, 14]. The ultimate eﬀect of MAPK activation
can range from cell proliferation to cell death and is
strongly inﬂuenced by the duration and magnitude of their
direct phosphorylation. MAPK phosphorylation depends
on an equilibrium state between the activity of upstream
kinases and speciﬁc MAPK phosphatases (MKPs). MKPs are
a group of protein phosphatases, including tyrosine, ser-
ine/threonine,anddual-speciﬁcityMAPKphosphatases,that
dephosphorylate MAPKs and block the signalling pathways
on which they depend. ROS, in addition to being able to
promote MAPK phosphorylation, are known to inhibit the
activity of MKPs through the reversible oxidation of their
reactive cysteine residues, thus contributing to a prolonged
activation of MAPKs [15]. There are three main MAPK
cascades in mammals: those mediated by the extracellular
signal-regulated kinases (ERK1/2), the c-Jun NH2-terminal
kinases or stress-activated kinases (JNK/SAPK) and p38.
The ERK cascade is mainly involved in the control of cell
proliferation and diﬀerentiation, whereas the p38 and JNK
pathwaysareimplicatedinthecontrolofcellsurvivalandcell
death because they are activated by environmental stresses,
which are often associated with the generation of ROS [16,
17].
5. Modulation of Quality
ControlinMitochondria
Numerous ﬁndings have suggested that disruptions in mito-
chondrial function and dynamics contribute to ageing and
neurodegenerative diseases (reviewed in [22]). Cells have
therefore developed molecular mechanisms to cope with
the diverse challenges imposed on mitochondrial integrity.
Mitochondria are thought to have at least two levels of
defence mechanisms that ensure their integrity and viability
in individual cells (reviewed in [23]). The ﬁrst line of
defence comprises highly speciﬁc molecular quality control
machinery, including molecular chaperones and proteases
that monitor the folding and assembly of mitochondrial
proteins. Interestingly, both PINK1 and HTRA2 seem to
be important modulators of molecular quality control in
mitochondria. The deletion of HTRA2 from mice results in
an increase in ROS levels and an accumulation of misfolded
proteins in brain mitochondria [24], and an analysis of
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Figure 1: Mutations in HTRA2 associated with Parkinson’s disease
lie in close proximity to p38 and CDK5 phosphorylation sites.
Mutations in the amino-terminus (A141S [6] and P143A [18]) and
the PDZ domain (G399S [6] and R404W [19]) are indicated. The
relative positions of the phosphorylation sites in human HTRA2
(see[20,21])areindicatedbythecirclesabovetheserineresidues.A
sequence alignment with HTRA2 orthologues from several species
is shown.
mutations in PINK1 revealed an increase in the levels of
misfolded mitochondrial respiratory complexes in the brain
[25].
Once mitochondrial molecular quality control is over-
whelmed, a second line of defence, termed organellar quality
control, is thought to take over. Organellar quality control
reliesonthedynamicnatureofmitochondrialpopulationsto
ensure the disposal of defective mitochondrial components
via mitochondrial ﬁssion and autophagy (reviewed in [3]).
Mitochondrial dynamics are thought to be important for
the control of mitochondrial turnover and bioenergetic
eﬃciency. The combined functions of fusion, ﬁssion, and
autophagy are now emerging as essential organellar quality
control mechanisms that promote the sequestration, sorting,
and elimination of functionally impaired mitochondria [26].
PINK1 seems to play a key role in organellar quality control.
PINK1 is capable of recruiting parkin, a cytosolic ubiq-
uitin ligase, to damaged mitochondria and targeting these
organelles for autophagic clearance [27].
If both molecular and organellar quality control mech-
anisms fail, severe mitochondrial damage can lead to the
uncontrolled release of mitochondrial proteins including
cytochrome c. Once it reaches the cytosol, cytochrome c
unleashes the apoptosis pathway of cell death (reviewed in
[28]).
Itisconceivablethatafailureofeitheroneofthesequality
control mechanisms in mitochondria ultimately results in
the demise of dopaminergic neurons observed in PD and
therefore plays a causative role in this disease.
6. Activation of Mitochondrial Damage
Responses by the p38 Stress Kinase
As stated above, it is conceivable that upon mitochondrial
damage, intracellular mechanisms act to convey a signal to
damage suppressors to attempt to counteract such damage.
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Figure 2: Modulation of mitochondrial quality control by the p38 stress kinase. When mitochondrial stress occurs, ROS production results
in the activation of p38. Through its downstream eﬀectors, PINK1 and CDK5, this pathway results in an increase in the proteolytic activity
of mitochondrial HTRA2, which in turn contributes to the suppression of mitochondrial damage by enhancing protein quality control. By
promoting the recruitment of cytosolic parkin to damaged mitochondria, PINK1 can also contribute to the clearance of these organelles
through mitophagy. Antioxidant systems modulate the levels of ROS and can therefore aﬀect signalling from p38 to either PINK1 or CDK5.
Yellow: mitochondrial proteins; cyan: cytosolic proteins.
kinase may ﬁt the role of such an intracellular sensor mech-
anism by conveying signals to mitochondrial proteins, such
as the putative kinase PINK1 and the protease HTRA2, to
activate mitochondrial quality control defence mechanisms.
Disease-causing mutations in PINK1 are linked to familial
PD [5], whereas HTRA2 mutations were reported to be
present in sporadic PD patients [6, 19].
A role for HTRA2 as a proapoptotic factor was ini-
tially described by several groups [29–32]. However, more
recently, in vivo studies in mice with a loss-of-function
mutation in the HTRA2 gene (S276C) and in HTRA2
knockout mice showed that these animals are characterised
by a lethal neurodegenerative disorder [33, 34]w i t ha n
accumulationofunfoldedproteinsinthemitochondria [24].
This indicates that the activity of mitochondrial HTRA2
protease may be important for controlling the levels of
misfolded proteins in mitochondria in a manner similar to
its bacterial homologues DegP and DegS [35, 36]. As with
many other proteases, the proteolytic activity of HTRA2 is
tightly regulated to prevent unwanted proteolysis. Structural
studies have shown that interactions between its protease
domain and its regulatory PDZ domain keep the proteolytic
activity of HTRA2 in check until the PDZ domain is engaged
by binding to C-terminal PDZ-binding peptides or internal
hydrophobic stretches in misfolded proteins [35, 36]. The
activation of HTRA2 has also been shown to occur via
the direct phosphorylation of S142 through an interaction
with PINK1 [20]. This PINK1-mediated phosphorylation
promoted by p38 results in an increase in HTRA2 proteolytic
activity, which, in turn, increases its protective eﬀects in
mitochondria.
More recently, a novel phosphorylation site (S400) has
been identiﬁed in HTRA2 [21]. This site lies in the PDZ
domain of the protease, a region known to modulate its
protease function [37], which may also be involved in
neuroprotection [20]. Phosphorylation of HTRA2 at S400
is promoted by CDK5, a serine/threonine kinase that is a
member of the highly conserved family of cyclin-dependent
kinases. This kinase is unique among its family members
because it is neither activated by cyclins nor regulates the
cell cycle (reviewed in Dhavan and Tsai [38]). Mice lacking
CDK5 die prematurely and demonstrate a disruption in
neuronal layering [39]. Abnormal CDK5 activity is associ-
ated with several neurodegenerative diseases. In particular,
CDK5 accumulates in neurons in Lewy bodies, the principal
hallmark of PD. CDK5-dependent HTRA2 phosphorylation
viathep38pathwayisinvolvedinmaintainingthemitochon-
drial membrane potential under stressful conditions and
results in protection against cellular stress [21].
Curiously, the mutations in the HTRA2 gene found in
PD patients seem to lead to amino acid changes in residues
that lie in close proximity to the identiﬁed phosphorylation
sites in this protease. Both the A141S [6] and the P143A
[18] mutations found in PD patients are near S142, whereas
G399S [6] and R404W [19] are near the S400 phospho-
rylation site (Figure 1). These ﬁndings suggest that such
mutations may aﬀect the phosphorylation status of HTRA2
and therefore have a detrimental role in the activation of this
enzyme downstream of p38 signalling.
7. Concluding Remarks
Taken together, the ﬁndings outlined in this paper are
suggestiveofaroleforthep38pathwayinmodulatingmolec-
ular quality control in mitochondria. It is conceivable
that following mitochondrial stress, mild ROS production
results in the activation of a mitochondrial damage-sensing
mechanism involving p38. This activation conveys a sig-
nal to downstream damage suppressors via PINK1 and
CDK5, resulting in an increase in the proteolytic activityInternational Journal of Cell Biology 5
of mitochondrial HTRA2, which then contributes to the
suppression of mitochondrial damage by increasing the
disposal of damaged mitochondrial components, such as
misfolded proteins (Figure 2). Failure to activate such a
pathway would result in an accumulation of mitochondrial
damage and perhaps result in overwhelming levels of ROS.
Such high levels of ROS would ultimately lead to the loss
of integrity of the mitochondrial membranes, causing the
release of proapoptotic proteins and eventual cell death.
Clearly, protein misfolding plays an important role in the
development of PD. Although clear mechanisms for such
protein misfolding pathologies are well established when
accumulation occurs in the cytosol, cell nucleus, endoplas-
mic reticulum, and extracellular space, little is known about
anycausativeroleofproteinaggregationinthemitochondria
in PD.
Neurodegenerative diseases are a group of adult-onset
pathologies of increasing clinical interest, considering the
growing number of new cases each year and the increasing
human lifespan, as age is one of the main risk factors. After
many years of research, the crucial role of mitochondria in
neurodegeneration has been established and is now widely
accepted. Mutations of mitochondrial proteins or proteins
involved in mitochondrial function have been found in
familiar cases of such diseases, but the role of many of those
proteins is still unclear. For example, HTRA2 is strongly
implicated in neurodegeneration, in particular PD, but this
has not been accompanied by a complete characterisation
of its activity. A deeper comprehension of the role of the
proteins involved in the control of mitochondrial home-
ostasis could provide better knowledge of the molecular
mechanisms underlying the development of neurodegener-
ative disorders associated with mitochondrial dysfunction
and could help the development of novel strategies able to
eﬀectively block the course of the disease.
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